Wed, 21 June 2017
AbbVie is developing new drugs to sidestep expiring patents on its best-seller, and a new FDA approval could be on deck at Clovis Oncology. Also, how Novartis plans to shake-up a multibillion dollar indication. |
Categories
PodcastArchives
December
S | M | T | W | T | F | S |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
5 | 6 | 7 | 8 | 9 | 10 | 11 |
12 | 13 | 14 | 15 | 16 | 17 | 18 |
19 | 20 | 21 | 22 | 23 | 24 | 25 |
26 | 27 | 28 | 29 | 30 |
Syndication
Wed, 21 June 2017
AbbVie is developing new drugs to sidestep expiring patents on its best-seller, and a new FDA approval could be on deck at Clovis Oncology. Also, how Novartis plans to shake-up a multibillion dollar indication. |